November 30, 2012 / 12:40 PM / 5 years ago

Teva's 2013 outlook misses estimates

Nov 30 (Reuters) - Teva Pharmaceutical Industries Ltd , the world's biggest generic drugmaker, forecast profit and revenue for the calendar 2013 that fell short of analysts' estimates.

The Israel-based company, which posted a quarterly profit above market estimates earlier this month on strong U.S. revenue, expects an adjusted profit of $4.85 to $5.15 per share in 2013 on revenue of $19.5 billion to $20.5 billion.

Analysts were expecting earnings of $5.71 per share, on revenue of $20.85 billion, according to Thomson Reuters I/B/E/S.

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below